- cafead   May 24, 2024 at 11:32: AM
via Four patients died in Johnson & Johnson’s Phase I study for its investigational targeted radiopharmaceutical candidate JNJ-6420 in metastatic castration-resistant prostate cancer, according to a Thursday readout released ahead of next week’s American Society of Clinical Oncology annual meeting.
article source
article source